Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. New Engl J Med. 2015;373:1541–52.

Article  CAS  PubMed  Google Scholar 

Kunstreich M, Kummer S, Laws HJ, Borkhardt A, Kuhlen M. Osteonecrosis in children with acute lymphoblastic leukemia. Haematologica. 2016;101:1295–305.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattano LA Jr, Devidas M, Nachman JB, Sather HN, Hunger SP, Steinherz PG, et al. Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. Lancet Oncol. 2012;13:906–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mostoufi-Moab S, Halton J. Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatment. Curr Osteoporos Rep. 2014;12:300–12.

Article  PubMed  PubMed Central  Google Scholar 

Niinimäki T, Harila-Saari A, Niinimäki R. The diagnosis and classification of osteonecrosis in patients with childhood leukemia. Pediatr Blood Cancer. 2015;62:198–203.

Article  PubMed  Google Scholar 

Parasole R, Valsecchi MG, Silvestri D, Locatelli F, Barisone E, Petruzziello F, et al. Correspondence: osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP). Blood Cancer J. 2018;8:115.

Article  PubMed  PubMed Central  Google Scholar 

Badhiwala JH, Nayiager T, Athale UH. The development of thromboembolism may increase the risk of osteonecrosis in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:1851–4.

Article  CAS  Google Scholar 

Finkelstein Y, Blonquist TM, Vijayanathan V, Stevenson KE, Neuberg DS, Silverman LB, et al. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017;64:e26393.

Article  Google Scholar 

Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11:1096–106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu C, Kawedia JD, Cheng C, Pei D, Fernandez CA, Cai X, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia. 2012;26:2303–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Relling MV, Yang W, Das S, Cook EH, Rosner GL, Neel M, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol. 2004;22:3930–6.

Article  PubMed  Google Scholar 

Albertsen BK, Grell K, Abrahamsson J, Lund B, Vettenranta K, Jónsson ÓG, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study. J Clin Oncol. 2019;37:1638–46.

Article  CAS  PubMed  Google Scholar 

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, et al. Reduced-intensity delayed intensification in standard-risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: results of an international randomized trial (AIEOP-BFM ALL 2000). J Clin Oncol. 2018;36:244–53.

Article  CAS  PubMed  Google Scholar 

Finch ER, Smith CA, Yang W, Liu Y, Kornegay NM, Panetta JC, et al. Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020;67:e28040.

Article  CAS  PubMed  Google Scholar 

Janke LJ, Van Driest SL, Portera MV, Atreya RV, Denny JC, Pei D, et al. Letter: Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. Blood. 2019;134:983–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, Cheng C, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2011;117:2340–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattano LA Jr, Sather HN, Trigg ME, Nachman JB. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children’s Cancer Group. J Clin Oncol. 2000;18:3262–72.

Article  PubMed  Google Scholar 

Mogensen SS, Harila-Saari A, Mäkitie O, Myrberg IH, Niinimäki R, Vestli A, et al. Comparing osteonecrosis clinical phenotype, timing, and risk factors in children and young adults treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018;65:e27300.

Article  PubMed  Google Scholar 

Niinimäki RA, Harila-Saari AH, Jartti AE, Seuri RM, Riikonen PV, Pääkkö EL, et al. High body mass index increases the risk for osteonecrosis in children with acute lymphoblastic leukemia. J Clin Oncol. 2007;25:1498–504.

Article  PubMed  Google Scholar 

Sakamoto K, Imamura T, Kihira K, Suzuki K, Ishida H, Morita H, et al. Low incidence of osteonecrosis in childhood acute lymphoblastic leukemia treated with ALL-97 and ALL-02 study of Japan Association of Childhood Leukemia Study Group. J Clin Oncol. 2018;36:900–7.

Article  CAS  PubMed  Google Scholar 

te Winkel ML, Pieters R, Hop WCJ, de Groot-Kruseman HA, Lequin MH, van der Sluis IM, et al. Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2011;29:4143–50.

Article  Google Scholar 

Yao S, Zhu Q, Cole PD, Stevenson K, Harris MH, Schultz E, et al. Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. Blood Adv. 2021;5:451–8.

Article  PubMed  PubMed Central  Google Scholar 

French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2008;111:4496–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Karol SE, Yang W, Van Driest SL, Chang TY, Kaste S, Bowton E, et al. Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. Blood. 2015;126:1770–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ramsey LB, Pounds S, Cheng C, Cao X, Yang W, Smith C, et al. Genetics of pleiotropic effects of dexamethasone. Pharmacogenet Genomics. 2017;27:294–302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang W, Devidas M, Liu Y, Smith C, Dai Y, Winick N, et al. Letter: Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. Blood. 2021;137:1550–2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valtis YK, Stevenson KE, Place AE, Silverman LB, Vrooman LM, Gotti G, et al. Orthopedic toxicities among adolescents and young adults treated on DFCI ALL Consortium trials. Blood Adv. 2022;6:72–81.

Article  CAS  PubMed  Google Scholar 

Seibel NL, Steinherz PG, Sather HN, Nachman JB, DeLaat C, Ettinger LJ, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Blood. 2008;111:2548–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children’s Oncology Group study AALL0232. J Clin Oncol. 2016;34:2380–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.

Article  Google Scholar 

Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977;35:1–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16:1141–54.

Article  Google Scholar 

Lynggaard LS, Rank CU, Hansen SN, Højfeldt SG, Henriksen LT, Jarvis KB, et al. Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study. Blood Adv. 2022;6:138–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Panetta JC, Cai X, Yang W, Pei D, Cheng C, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol. 2008;26:1932–9.

Article  CAS  PubMed  Google Scholar 

Chen S-H, Pei D, Yang W, Cheng C, Jeha S, Cox NJ, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity. Clin Pharmacol Ther. 2010;88:191–6.

Article  CAS  PubMed